Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06441643 · ClinicalTrials.gov registry record · Phase 2
Next Generation Rocklatan
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 426
- Enrollment target
NCT06441643: Completed Phase 2 study, sponsored by Alcon Research.
NCT06441643 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 426 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (220% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06441643, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 426 participants
- Enrollment target
Study Summary
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Primary Outcome
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the four measurements.
Interventions
- DRUG Latanoprost 0.005% Ophthalmic Solution
- DRUG Netarsudil 0.02% Ophthalmic Solution
- DRUG AR-17043 Ophthalmic Solution
- DRUG PG043 Ophthalmic Solution
- DRUG Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2024-09-04 |
| Est. Completion | 2025-11-14 |
| Phase | Phase 2 |
What the finished NCT06441643 record still lists
NCT06441643 is an interventional study that assigns participants to a tested intervention. The registered 426 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (220% higher).
The record links to 0 conditions, and to 5 interventions - of which Latanoprost 0.005% Ophthalmic Solution is the first listed.
NCT06441643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06441643 about?
NCT06441643 is a clinical study titled "Next Generation Rocklatan". The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
What is the current status of trial NCT06441643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 426 participants. The study started on 2024-09-04. Estimated completion is 2025-11-14.
What interventions are being tested in trial NCT06441643?
The interventions under investigation include: Latanoprost 0.005% Ophthalmic Solution (DRUG), Netarsudil 0.02% Ophthalmic Solution (DRUG), AR-17043 Ophthalmic Solution (DRUG), PG043 Ophthalmic Solution (DRUG), Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT06441643?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06441643's enrollment target sits among peer trials
426 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790784 · 426 participants · Phase 3
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI